-
Valeant's Post-Ackman Recovery Is Characterized By 'Less Money, More Problems'
Tuesday, March 21, 2017 - 10:02am | 421Billionaire investor Bill Ackman cut his losses in Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock so now is the time for both the company and hedge fund manager to move on. According to a Bloomberg report, Valeant's path forward is difficult and characterized by the company having less money...
-
A Deeper Look Into Valeant's Assets As It Searches For Salix Buyer
Wednesday, November 2, 2016 - 1:43pm | 382Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is reportedly shopping for buyers to acquire its Salix unit for an expected $8.5 billion and additional royalty payments in the future. Valeant is plagued with debt, causing some concern among shareholders so any cash infusion would certainly ease...
-
CIBC Analysts On Valeant: Questions Still Unanswered After Investor Day
Thursday, December 17, 2015 - 2:56pm | 413Valeant Pharmaceuticals Intl Inc (NYSE: VRX) recently held its Investor Day, where management provided revised guidance, in line with estimates. Following the event, CIBC analysts Prakash Gowd and Ryan Lee issued a Sector Perform rating and $90 price target on the shares. The experts commented...